Prime Medicine, Inc.

Prime Medicine, Inc. insiders are currently net buyers of PRME stock, showing bullish sentiment over the past 90 days. Executives have purchased $142.6M while selling $20.0M, resulting in a positive net flow of $122.6M. This buying activity represents 88% of total transaction volume.

Prime Medicine, Inc. has 27 active insiders who have filed SEC Form 4 transactions in the past 90 days. Robert Nelsen (Executive) leads with 8 transactions totaling $43.6M. Venture Partners X, L.p. Arch (Executive) follows with 1 transactions worth $20.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Prime Medicine, Inc.'s current score of 88/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $142.6M in purchases versus $20.0M in sales.

The most recent insider transaction occurred on Feb 23, 2026, when Alenson Carman (See Remarks) acquired 140,000 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, PRME insider trading sentiment is currently bullish with an Alignment Score of 88/100. The net insider flow of $122.6M reflects accumulation, with 88% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Prime Medicine, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At PRME, we track all Form 4 filings—currently showing 111 transactions from 27 insiders over 90 days.

A 10b5-1 plan allows Prime Medicine, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At PRME, approximately 28% of recent transactions are 10b5-1 trades. The remaining 72% are discretionary trades, which may carry more informational value.

You can monitor Prime Medicine, Inc. (PRME) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 27 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Prime Medicine, Inc.'s current score of 88/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $142.6M in purchases versus $20.0M in sales over 90 days, resulting in a net flow of $122.6M.

SEC Form 4 filings are mandatory reports that Prime Medicine, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At PRME, the most common type is "A" with 22 occurrences. The most recent Form 4 was filed on Feb 23, 2026 by Alenson Carman.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Prime Medicine, Inc., approximately 28% of recent transactions are executed under 10b5-1 plans, while 72% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.